Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Company news centers on its off-the-shelf cell-therapy pipeline, including prulacabtagene leucel, or prula-cel, a CD20-targeted CAR gamma delta T cell therapy, and ADI-212, a PSMA-targeted candidate.
Recurring updates also cover clinical and regulatory disclosures, operating and financial results, biotechnology conference participation, inducement equity grants under Nasdaq rules, shareholder voting matters, Nasdaq listing compliance, and capital-structure actions involving common stock.
Adicet Bio (ACET) granted a new employee an inducement award of stock options to purchase 725 common shares. The options have an exercise price of $7.14 per share, matching the Nasdaq closing price on September 30, 2026. One-fourth vests on the first anniversary of the employee’s start date; the remainder vests in thirty-six substantially equal monthly installments, with full vesting on the fourth anniversary, subject to continued employment.
The compensation committee authorized the award under the 2022 Inducement Plan, outside stockholder-approved equity incentive plans, in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (ACET) reported Phase 1 safety and efficacy findings for investigational prula-cel in patients with lupus with or without nephritis.
At the August 28, 2026 data cut, 22 patients were efficacy-evaluable, including 16 with lupus nephritis; 13 had at least 12 months of follow-up. At 12 months, 54% of evaluable patients achieved DORIS remission, and 50% of evaluable nephritis patients achieved complete renal response. All patients discontinued immunosuppressants; all but one tapered background steroids to 5 mg or less of prednisone equivalent per day.
Among 24 safety-evaluable patients, no cytokine release syndrome exceeded Grade 2. Infections occurred in 54%, including Grade 3 or higher infections in 8.3%. Adicet plans pivotal lupus nephritis trial start-up activities in the fourth quarter of 2026. Including patients without nephritis remains subject to regulatory alignment.
Adicet Bio (ACET) will report Phase 1 prula-cel clinical data in patients with systemic lupus erythematosus on September 28, 2026. The study includes patients with or without lupus nephritis. A webcast to discuss the results will follow at 8:00 a.m. ET.
Adicet Bio (ACET) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, held from September 14-16, 2026.
The session with President and CEO Chen Schor is scheduled for Tuesday, September 15, 2026 at 3:00 p.m. ET and will be available via live audio webcast on the Investors section of Adicet Bio’s website, with a replay accessible for 30 days.
Adicet Bio (Nasdaq: ACET) reported completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in systemic lupus erythematosus (SLE) with or without lupus nephritis, with topline data expected in September 2026.
The planned analysis will include 22 SLE patients with at least 6 months of follow-up, including 13 with at least 12 months. Adicet expanded prula-cel administration into the outpatient setting after FDA alignment and is developing a potential registrational trial design. The FDA cleared the IND for ADI-212 in metastatic castration-resistant prostate cancer, with Phase 1 enrollment planned for 4Q 2026. The company is also advancing a diversified in vivo CAR-T portfolio, with the first candidate expected to enter clinical development in the second half of 2027.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotechnology company focused on allogeneic gamma delta CAR T and in vivo CAR T therapies, reported an inducement stock option grant made on August 31, 2026 under Nasdaq Listing Rule 5635(c)(4). One new employee hired in August 2026 received non-qualified options to purchase 1,500 shares of common stock at an exercise price of $8.70 per share, equal to the Nasdaq closing price on August 31, 2026. One-fourth of the options will vest on the first anniversary of the employee’s start date, with the remaining three-fourths vesting in 36 substantially equal monthly installments over the following three years, subject to continued employment. The grant was made outside stockholder-approved equity plans under Adicet’s 2022 Inducement Plan and was approved by the independent compensation committee as a material inducement to employment.
Adicet Bio (Nasdaq: ACET) reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for ADI-212, an allogeneic gamma delta 1 CAR T cell therapy candidate for patients with metastatic castration-resistant prostate cancer (mCRPC). Phase 1 enrollment in mCRPC is expected to begin in the fourth quarter of 2026.
According to Adicet Bio, ADI-212 is a next-generation, gene-edited, off-the-shelf cell therapy targeting PSMA, engineered with membrane-tethered IL-12 armoring and CRISPR/Cas9-mediated disruption of MED12 to support tumor-specific recognition and multiple anti-tumor mechanisms in the tumor microenvironment.
Adicet Bio (Nasdaq: ACET) reported second quarter 2026 results and pipeline progress. For the quarter ended June 30, 2026, research and development expenses were $18.5 million, general and administrative expenses $3.9 million, and net loss $21.4 million, or $1.99 per basic and diluted share.
Cash, cash equivalents and short-term investments totaled $118.2 million, which the company expects will fund operations into the second half of 2027. Adicet plans a comprehensive Phase 1 update for prulacabtagene leucel (prula-cel) in LN and SLE in 3Q 2026, informed by productive FDA interactions on a potential pivotal LN trial. A regulatory filing for ADI-212 in mCRPC is expected in 3Q 2026, with Phase 1 enrollment anticipated in 4Q 2026, and an update on its in vivo CAR-T platform is planned for the second half of 2026. The company appointed Lloyd Klickstein, M.D., Ph.D. as Interim Chief Medical Officer.
Lipocine (NASDAQ: LPCN) appointed Michael J. Grissinger to its Board of Directors, effective August 3, 2026. The company develops therapeutics using a proprietary oral delivery technology platform.
Grissinger previously spent over two decades at Johnson & Johnson in senior roles leading worldwide pharmaceutical licensing, corporate development, and M&A, including heading Immunology business development and licensing. Earlier, he worked 12 years at Ciba-Geigy in finance, marketing, and business development. He currently serves on the boards of Aprea Therapeutics (Nasdaq: APRE) and Adicet Bio (Nasdaq: ACET), and advises several private biotech companies. According to Lipocine, his experience is expected to support advancement of its pipeline and partnership efforts.
Adicet Bio (Nasdaq: ACET) announced that President and CEO Chen Schor will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference, held August 11-13, 2026, in Boston.
The session is scheduled for Tuesday, August 11, 2026, at 10:30 a.m. ET, with a live audio webcast and 30-day replay available via the Investors section of Adicet Bio’s website.